Related Experiment Videos
Fixed duration MDT in paucibacillary leprosy (classical and modified)
Abstract:
We analyzed the records of 1022 patients of paucibacillary leprosy who had received either 6 doses of WHO-MDT alone (" classical" MDT, 668 patients) or had post-MDT dapsone for at least 6 months ("modified" MDT, 354 patients). The duration of posttherapy surveillance ranged from 6 months to 7 years (mean 20.4 months). We found that the incidence of unfavorable events was significantly higher with the classical regimen when patients were graded as active at the end of the fixed duration regimen, especially when patients with > 2 lesions were considered. In the patients who were graded as inactive at the end of 6 doses, there was a slight excess of unfavorable events in the modified regimen, although not statistically significant. No correlation was found between unfavorable events and the regularity of treatment or the lepromin status. Overall, the incidence of adverse events was higher in patients with multiple lesions, and more than 90% of the adverse events occurred during the first 2 years of follow up. It is felt that 6 doses of MDT is adequate in the majority of patients who have few lesions or who have become inactive at the end of the treatment period. However, caution should be exercised in those with multiple lesions or in those considered active at the end of 6 doses.
Insights
Six doses of World Health Organization-Multidrug Therapy (WHO-MDT) may be sufficient for paucibacillary leprosy patients with few lesions or inactive disease. However, those with multiple lesions or active disease require careful monitoring for unfavorable events.
Area of Science:
- Dermatology
- Infectious Diseases
- Public Health
Background:
- Paucibacillary leprosy treatment typically involves a fixed duration of World Health Organization-Multidrug Therapy (WHO-MDT).
- The optimal duration and post-therapy management strategies require ongoing evaluation to minimize unfavorable events.
Purpose of the Study:
- To compare the incidence of unfavorable events between classical WHO-MDT and a modified regimen with post-therapy dapsone in paucibacillary leprosy patients.
- To identify patient subgroups at higher risk for adverse outcomes following leprosy treatment.
Main Methods:
- Retrospective analysis of 1022 paucibacillary leprosy patients.
- Comparison of outcomes between patients receiving 6-dose WHO-MDT alone versus those with at least 6 months of post-MDT dapsone.
- Surveillance duration ranged from 6 months to 7 years.
Main Results:
- Higher incidence of unfavorable events observed with classical MDT in patients active at treatment completion, particularly those with >2 lesions.
- A non-significant trend of increased unfavorable events in the modified regimen for inactive patients.
- Adverse events were more common in patients with multiple lesions and primarily occurred within the first 2 years of follow-up.
Conclusions:
- Six-dose WHO-MDT appears adequate for most paucibacillary leprosy patients with limited lesions or inactive disease post-treatment.
- Caution and closer monitoring are advised for patients with multiple lesions or those remaining active after 6-dose MDT.
- Treatment regularity and lepromin status did not correlate with unfavorable events.